Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. - Wikidata - wikimedia - TriplyDB

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

http://www.wikidata.org/entity/Q38205707

about

Treatment of complex regional pain syndrome type I with bisphosphonates Bisphosphonate therapy in pediatric patients Management of endocrine disease: Secondary osteoporosis: pathophysiology and management Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature Haemoglobinopathies and the rheumatologist Thalassemia 2016: Modern medicine battles an ancient disease.The importance of nutrition for health in patients with transfusion-dependent thalassemia.Management of beta-thalassemia-associated osteoporosis.Which pamidronate protocol is the best for treating osteoporosis in beta-thalassemia major?Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.Zoledronic Acid for Treatment of Low Bone Mineral Density in Patients with Beta Thalassemia Major

P2860

Q26777904-A12842F9-CE60-444E-9A15-BC5A8A05927F Q26830702-94082A9A-8B9E-4FAC-9676-C64F395618BE Q26998249-C46964EB-928A-4DD3-A249-EFDCA5817973 Q28071432-C516B02C-9B54-4ADB-9F95-040B509614D3 Q28075506-FEE74ECC-EA05-4B2F-BAA7-435D57CE4E88 Q38625435-8B8B3D1D-9561-4A19-9FAF-6B1F70A874E0 Q38715841-03A610E0-6AA2-4D50-8B0F-F415D768C414 Q38802918-9E25E38F-4CEA-4EA3-9C9B-C210243467D1 Q40248622-B25C72FE-9DC8-4CB4-99BC-6E26FCA6648D Q40703352-10BE4422-494B-4CD6-923E-1667EED5666F Q58125050-8939DB7A-B62D-4BEC-AE8E-469D794350BC

P2860

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

http://www.wikidata.org/entity/Q38205707

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Bisphosphonates in the managem ...... randomised controlled trials.

@en

type

label

Bisphosphonates in the managem ...... randomised controlled trials.

@en

prefLabel

Bisphosphonates in the managem ...... randomised controlled trials.

@en

P1433

Q38205707-15101F96-9935-4A27-A6CF-44EB37B4B0EE

P1476

Q38205707-D3970718-60E3-4249-9768-6796C6371B9D

P2093

Q38205707-E4065863-FCFB-4617-AC99-B9B00C3AB8FC

P2860

Q38205707-0683402F-A093-4D28-BDB6-506919E52986

Q38205707-098B171F-D981-467C-BF9C-3D220874E852

Q38205707-0F278A08-286B-4FAD-95FE-70540AE5DC6D

Q38205707-0FC6DD97-12BB-498A-8E86-3F7815189233

Q38205707-13239378-C6E3-4434-A43A-613B3C726827

Q38205707-15ABBEE4-FF3E-4F28-94F7-9EA0D3083126

Q38205707-16AD34C2-162B-46DC-881A-CC403DD77D6A

Q38205707-16B49731-1359-4BDA-98CA-09175683D68A

Q38205707-1B09FC7B-4936-4888-9722-27088E7082F3

Q38205707-1F421735-2BA3-44BD-99F3-007168BA018E

P2888

Q38205707-FA338B6B-878A-47DD-AB59-0AFEB3391606

P304

Q38205707-D7EDD128-8C5C-43F0-BB53-83589252EE65

P31

Q38205707-DBCA5B77-170A-4691-88FA-78295EEEFB9E

P356

Q38205707-23287F51-63F1-49AB-BA14-9A5AD85219FE

P433

Q38205707-6F50E618-2D7B-4919-A6E1-136577D3F9BB

P478

Q38205707-2CFF3008-2947-4CE4-9815-0A5A6A016DD0

P577

Q38205707-0622C736-FC92-4401-B256-9E8F3235323C

P698

Q38205707-756B9DD5-3830-46C3-B55D-81DE1FD99691

P921

Q38205707-3D50CCA1-1528-4703-B57C-222E29BF0884

P356

S00774-014-0584-8

P1433

Journal of Bone and Mineral Metabolism

P1476

Bisphosphonates in the managem ...... randomised controlled trials.

@en

P2093

Andrea Giusti

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-thalassemia

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Bone disease in thalassemia: a frequent and still unresolved problem.

Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Zoledronic acid and clinical fractures and mortality after hip fracture.

New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia.

P2888

s00774-014-0584-8

P304

606-615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00774-014-0584-8

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24748165

http://www.w3.org/2001/XMLSchema#string

P921